Nuvalent (NUVL) CDO exercises options and sells 23,000 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Nuvalent, Inc.’s Chief Development Officer Darlene Noci exercised stock options and sold shares of Class A Common Stock. On July 1, 2026, she exercised options for a total of 23,000 shares at exercise prices of $72.35 and $18.93 per share, then sold 23,000 shares in an open-market transaction at a weighted average price of $123.59 per share. After these transactions, she directly owned 58,117 shares of Class A Common Stock. The filing notes the transactions were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 23,000 shares ($2,842,570)
Net Sell
5 txns
Insider
Noci Darlene
Role
Chief Development Officer
Sold
23,000 shs ($2.84M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 9,146 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 13,854 | $0.00 | -- |
| Exercise | Class A Common Stock | 9,146 | $18.93 | $173K |
| Exercise | Class A Common Stock | 13,854 | $72.35 | $1.00M |
| Sale | Class A Common Stock | 23,000 | $123.59 | $2.84M |
Holdings After Transaction:
Stock Option (Right to Buy) — 15,112 shares (Direct, null);
Class A Common Stock — 67,263 shares (Direct, null)
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.51 to $123.62, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price. The shares underlying this option are fully vested. The shares underlying this option have vested or shall vest over the four years following January 5, 2024 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
Key Figures
Shares sold: 23,000 shares
Sale price (weighted average): $123.59 per share
Options exercised at $72.35: 13,854 shares
+5 more
8 metrics
Shares sold
23,000 shares
Class A Common Stock sold on July 1, 2026
Sale price (weighted average)
$123.59 per share
Open-market sale range $123.51–$123.62
Options exercised at $72.35
13,854 shares
Stock Option (Right to Buy), exercise price $72.35
Options exercised at $18.93
9,146 shares
Stock Option (Right to Buy), exercise price $18.93
Post-transaction holdings
58,117 shares
Class A Common Stock held directly after transactions
10b5-1 plan adoption date
November 18, 2024
Plan governing the reported transactions
Option expiration
January 5, 2034
Expiration date for $72.35 exercise price option
Option expiration
January 4, 2032
Expiration date for $18.93 exercise price option
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), Chief Development Officer
4 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" in the derivative transaction records"
Chief Development Officer other
"officer_title: "Chief Development Officer" for reporting person Darlene Noci"
Chief development officer is the senior executive who leads a company's efforts to create and grow future revenue streams, whether by developing new products, forging partnerships, or running clinical and regulatory programs in research-focused businesses. Investors watch this role because the officer shapes the pipeline and execution that determine future sales and risk — like a head gardener planning and tending crops that will produce tomorrow’s harvest.
FAQ
What insider transactions did Nuvalent (NUVL) report for Darlene Noci?
Nuvalent reported that Chief Development Officer Darlene Noci exercised options for 23,000 shares and sold 23,000 Class A Common shares on July 1, 2026. These trades combined option exercises with an open-market sale under a pre-arranged plan.
What stock options did Darlene Noci exercise in this Nuvalent (NUVL) Form 4?
She exercised stock options for 13,854 shares at a $72.35 exercise price and 9,146 shares at an $18.93 exercise price. These option exercises converted derivative holdings into Class A Common Stock before the reported share sale.
What does the weighted average price mean in the Nuvalent (NUVL) Form 4?
The weighted average price of $123.59 reflects multiple individual trades between $123.51 and $123.62. The filing notes the insider will provide detailed share counts at each price to the SEC, Nuvalent, or any security holder upon request.